NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Neurodegenerative Drugs industry
http://www.reportlinker.com/p0197211/Global-Neurodegenerative-Drugs-industry.html
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 165 companies including many key and niche players such as Amarin Corporation PLC, AstraZeneca PLC, Avanir Pharmaceuticals, Inc., Avigen, Inc., Bayer Schering Pharma AG, Boehringer Ingelheim GmbH, Biogen Idec Inc., Bristol-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc., Elan Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Merck Serono SA, Mitsubishi Tanabe Pharma Corporation, Neurologix, Inc., NeuroSearch A/S, Novartis AG, Pfizer, Inc., Sanofi-aventis S.A, Shire Pharmaceuticals Group PLC, Teva Pharmaceutical Industries Limited, Valeant Pharmaceuticals International, and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
NEURODEGENERATIVE DRUGS MCP-6313
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Alzheimer's Disease I-3
Parkinson's Disease I-4
Multiple Sclerosis I-4
Amyotrophic Lateral Sclerosis I-4
Others I-4
Huntington's Disease I-4
Neuropathic Pain I-4
Prion Disease I-5
II. EXECUTIVE SUMMARY
1. GLOBAL MARKET OVERVIEW II-1
Global Market Analysis II-1
Global Market Analysis by Disease Type II-1
Neurodegenerative Drugs - The Next Big Thing in Healthcare II-2
Alzheimer's and Parkinson's Market II-2
Factors Affecting the Market II-3
Major Growth Drivers Ahead II-3
Major Growth Inhibitors II-3
Rapid Growth of Aging Population II-3
Table 1: Global 65+ Age Group Population in Millions
(includes corresponding Graph/Chart) II-4
Higher Alzheimer's and Parkinson's Prevalence II-4
Price Hikes and Government Caps II-4
Future Holds Promise! II-4
Research & Development II-5
Neuroscience Research Focused on Neurodegenerative Diseases II-5
Neuroscience Research Advances to Make a Mark II-6
Summary of Major Neuroscience Research Developments in 2009 II-6
2. A REVIEW OF SELECT NEURODEGENERATIVE DRUGS MARKETS II-7
A. Alzheimer's Market in Review II-7
The AD Epidemiology II-7
Table 2: World Alzheimer's Disease Prevalence by
Country/Region: Number of Patients in US, Canada, Japan,
Europe (Germany, France, UK, Italy, Spain and Rest of
Europe), Asia-Pacific (Australia, India, Philippines and
Rest of Asia-Pacific), Brazil and Rest of World in
Thousands for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-7
Table 3: Alzheimer's Disease Statistics in Top Seven
Countries (US, Japan, Germany, France, UK, Italy and
Spain): Number of Patients Diagnosed and Treated by Disease
Severity (Mild Stage, Moderate Stage, and Late Stage) in
Thousands for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-8
The Impact of Dementia II-8
A Look At AD Demographics II-8
A Global Overview II-9
Geographic Overview II-10
Growth Drivers II-10
Aging Baby Boomers - The Market's Growth Engine II-10
Table 4: AD Frequency Rates in the US and Europe:
Percentage Share by Age Group (includes corresponding
Graph/Chart) II-10
Unmet Medical Needs Drive Market Growth II-11
Growth Restrains II-11
Misdiagnosis II-11
Lack of Awareness II-11
High Cost of Treatment II-11
Market Outlook for Anti-AD Drugs II-11
Cholinesterase Inhibitors - The Leader, but Not Strong
Growth Contender II-12
NMDA Receptor Antagonists - Dynamic Growth Potential,
Albeit A Small Base II-12
Approval of Anti-AD Drugs (Cholinesterase Inhibitors) in
Select Countries II-13
Competitive Landscape II-13
B. The Parkinson's Market in Review II-14
The PD Epidemiology II-14
Table 5: World Parkinson's Disease Prevalence by
Country/Region: Number of Patients in the US, Canada,
Japan, Europe (Germany, France, UK, Italy, Spain and Rest
of Europe), China and Rest of World in Thousands for Years
2001 through 2010 (includes corresponding Graph/Chart) II-14
A Global Overview II-15
Dominance of Dopamine Agonists II-15
Stalevo Continues to Outshine II-15
The Slippery Path to Clinical Success II-15
Market Drivers II-16
Emergence of Dopamine Agonists as First Line Treatment II-16
The Debut of Stalevo II-16
High Unmet Clinical Needs II-16
Market Inhibitors II-16
Lack of Awareness and Under-diagnosis II-16
Limitations of Existing Medicines II-17
Restricted Period Use of Dopamine Agonists II-17
Generic Competition from L-Dopa and Carbidopa II-17
C. The Multiple Sclerosis Market in Review II-17
The MS Epidemiology II-17
Table 6: World Multiple Sclerosis Prevalence in Thousands
by Select Countries for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-18
Facts About Multiple Sclerosis II-18
Market Overview II-19
Interferon-based Drugs Lead Multiple Sclerosis Drugs Market II-19
High Unmet Need and Rich Pipeline to Expand MS Market II-19
Sales Dip Inevitable for Current Therapies II-20
Tough Times Ahead for Betaseron II-21
Competitive Landscape II-21
Table 7: Global Multiple Sclerosis Market by Leading Drugs
(2008 & 2009): Percentage Share Breakdown for Copaxone,
Avonex, Rebif, Betaseron, and Tysabri (includes
corresponding Graph/Chart) II-21
D. The ALS Market in Review II-22
The ALS Epidemiology II-22
Market Overview II-23
Sanofi-aventis - The ALS Drugs Market Leader II-23
E. The Huntington's Market in Review II-23
The HD Epidemiology II-23
Market Outlook II-24
F. Neuropathic Pain Market in Review II-25
Market Overview II-25
G. Prion Disease II-25
Disease Origin II-25
3. FUTURE THERAPIES II-26
Alzheimer's Disease II-26
Select Pipeline Drugs for Alzheimer's Disease II-26
Parkinson's Disease II-26
Select Pipeline Drugs for Parkinson's Disease II-27
Huntington's Disease II-27
Select Pipeline Drugs for Treatment of Huntington's Disease II-27
Multiple Sclerosis II-28
Oral Pipeline Drugs to Alter Market Dynamics in MS Therapies II-28
Select Pipeline Drugs for Multiple Sclerosis II-29
Amyotrophic Lateral Sclerosis II-29
Select Pipeline Drugs for Amyotrophic Lateral Sclerosis II-29
4. NEURODEGENERATIVE DISEASES OVERVIEW II-30
Neurodegeneration II-30
An Overview of Factors that Link Neurodegenerative Diseases II-30
Genetics II-30
Intracellular Mechanisms II-30
Protein Degradation Pathways II-30
Mitochondrial Dysfunction II-31
Axonal Transport II-31
Programmed Cell Death II-31
An Overview of Select Major Neurodegenerative Diseases II-32
Alzheimer's Disease II-32
Definition II-32
Cause II-33
Diagnoses II-33
Prevention II-33
Treatment II-33
Anti-AD Drug Classes and Approved Products II-34
Parkinson's Disease II-34
Definition II-34
Cause II-34
Diagnosis II-35
Therapeutic Treatment II-35
List of Drugs Available for the Treatment of Parkinson's
Disease II-35
Surgical Intervention II-36
Multiple Sclerosis II-36
Definition II-36
Types of Multiple Sclerosis II-36
Table 8: Prevalence of Different Types of Multiple
Sclerosis (includes corresponding Graph/Chart) II-37
Etiology II-37
Pathology II-37
Treatment II-38
List of Approved Multiple Sclerosis Drugs II-38
Huntington's Disease II-38
Definition II-38
Prognosis II-39
The Three Stages of HD II-39
Symptoms and Signs II-40
List of Physical, Psychiatric and Cognitive Symptoms in
Huntington's Disease II-40
Diagnosis II-40
Treatment II-41
Amyotrophic Lateral Sclerosis (ALS) II-41
Definition II-41
Types of ALS II-42
Familial ALS II-42
Sporadic ALS II-42
Guamanian ALS II-42
Etiology II-42
Symptoms II-43
Diagnosis II-44
Treatment II-44
5. AN OVERVIEW OF NEURODEGENERATIVE DRUGS FOR SELECT DISEASES II-46
Neurodegenerative Drugs for Alzheimer's Disease II-46
NMDA Receptor Antagonists (NMDARA) II-46
Memantine II-46
Cholinesterase Inhibitors (ChEIs) II-47
Donepezil (Aricept) II-47
Rivastigmine (Exelon) II-47
Galantamine Hydrobromide (Razadyne) II-47
Tacrine (Cognex) II-48
Other Alternatives II-48
Vitamin E II-48
Estrogen Therapy II-48
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) II-48
Gingko Biloba II-49
Neurodegenerative Drugs for Parkinson's Disease II-49
Dopaminergic Agents II-49
Levodopa/Carbidopa II-49
Dopamine Agonists II-50
Bromocriptine/Parlodel II-50
Ropinirole/Requip II-50
Pramipexole/Mirapex II-50
Cabergoline/Dostinex II-50
Apomorphine/Apokyn II-50
Other PD Drugs II-51
COMT Inhibitors II-51
MAO-B Inhibitors II-51
Dopamine Amplifiers II-51
Anticholinergics II-52
Neurodegenerative Drugs for Huntington's Disease II-52
Tetrabenazine II-52
Others II-53
Neurodegenerative Drugs for Multiple Sclerosis II-53
Interferon Drugs II-53
Beta Interferon Drugs for the Treatment of Multiple Sclerosis II-54
Non-Interferon Drugs II-54
Non-Interferon Drugs for the Treatment of Multiple Sclerosis II-54
Neurodegenerative Drugs for Amyotrophic Lateral Sclerosis II-54
Rilutek II-55
Symptomatic Treatment II-55
6. NEURODEGENERATIVE RESEARCH II-57
Neurologix's Non-dopamine Gene Therapy for PD II-57
Cell Cure's Cell Replacement Therapy for PD II-57
Researches Developing Neuroprotective Agent for PD II-57
UT Southwestern Researchers Study New Compound for HD II-58
UCLA Scientists Identify Molecular Switch Capable of Blocking HD II-58
Repligen Reports Detection of HDAC 3 Drug Target for
Friedreich's Ataxia (US) II-58
Tel Aviv University Reports Stem Cell Cure for
Neurodegeneration (Israel) II-59
Cambridge Researchers Develop Novel Drug Targets for HD II-59
Emory Research Team Develops First Transgenic Monkey Model of HD II-59
KeyNeurotek Pharma Discloses Molecular Pathomechanism of HD
Mutation II-60
Researchers Identify New Gene for ALS II-60
Q Therapeutics and Johns Hopkins Research Team to Study GRPs
in ALS Model II-60
ALS TDI and CSC Collaborate to Study Stem Cells Use in ALS
Treatment II-61
Allen Institute and ALS TDI to Conduct ALS Study II-61
Life Technologies to Develop Neurodegenerative Disease Models II-61
Neuralstem and University of Michigan Collaborate for ALS
Research II-62
ALS TDI and MDA Collaborate for ALS Drug Discovery II-62
7. SELECT CLINICAL TRIALS II-63
Novartis Obtains Priority Review Status for Oral Fingolimod
from US FDA II-63
Medivation's Dimebon Fails to Meet End Points in Phase III Trial II-63
QR Pharma Annuls Phenserine Production II-63
Neurologix Begins Phase II Studies for Parkinson's Disease
Treatment (US) II-64
Biovail and ACADIA Complete Phase II Clinical Trials for
Pimavanserin (Canada, US) II-64
Merck Serono Announces Encouraging Phase III Results of Oral
Mylinax II-64
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT II-64
NeuroSearch Presents ACR16 as Novel Huntington's Disease Therapy II-65
Eli Lilly Launches Two Phase-III Trials for Solanezumab(i)
Worldwide (US) II-66
Teva and Active Biotech Obtains Fast Track Status from FDA for
Oral Laquinimod II-66
CytRx Initiates Phase II/III Clinical Trial for Arimoclomol II-67
Synosia Therapeutics Starts Stage-I Clinical Trial for SYN-120
(Switzerland) II-67
H. Lundbeck Begins Phase-I Clinical Tests for Lu 02-750 (Denmark) II-67
Anavex Life Sciences Selects FORENAP Pharma EURL for ANAVEX 2
-73 Phase-I Clinical Tests (Switzerland) II-67
Bayer Schering Pharma Completes Stage-II Trials for BAY 94-
9172 (Germany) II-68
Newron and Merck Serono Start Second Round of Phase III Tests
for Safinamide (Italy) II-68
Biogen Idec Secures Fast Track Designation from US-FDA for
PEGylated Interferon Beta-1a II-68
ExonHit Therapeutics Completes Phase-II Clinical Study for EHT
0202 (France) II-68
Kyowa Hakko Kirin to Start Phase-III Clinical Trials for
Istradefylline in Japan II-69
Medtronic and Alnylam Pharma Report Pre-Clinical Results of
ALN-HTT (US) II-69
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's
Treatment II-69
NeuroSearch Begins Critical Phase III Program with ACR16 II-70
Avicena to Proceeds with Phase III Trial of HD-02 II-70
Knopp Neurosciences Commences Phase II Study of KNS- 760704 II-70
Maas Biolab SBIR Initiates Phase II for Cyclosporin II-71
MediciNova Announces Phase II Clinical Trial Results of MN-166 II-71
Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02 II-71
EnVivo Pharmaceuticals Progresses on Major HDACi Program II-72
NeuroSearch Files CTA in Europe to Begin Clinical Phase III
Program with ACR16 II-72
8. PRODUCT INTRODUCTIONS/ APPROVALS/ DEVELOPMENTS II-73
Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to
treat Multiple Sclerosis II-73
Novartis Obtains Priority Review Status for Oral Fingolimod
from US FDA II-73
Accera Introduces Axona™ II-73
Eisai Receives Approval for Aricept® II-73
Copaxone Receives FDA Approval for Patients with First
Clinical Episode Suggestive of MS II-74
Copaxone Receives FDA Approval for Patients with First
Clinical Episode Suggestive of MS II-74
Novartis Obtains FDA Approval for Extavia II-74
ArmaGen Develops IgG-Decoy Receptor Fusion Protein (US) II-75
Knopp's KNS-760704 Receives EC Orphan Designation II-75
NeuroSearch Receives EMEA Approval for Huntexil™ Brand Name (
Europe) II-75
Cambridge Labs Receives Spanish Marketing Approval for
Tetrabenazine II-75
ArmaGen Technologies Secures Orphan Drug Designation for AGT-
181 from FDA (US) II-76
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation
for Cysteamine II-76
Elan and Biogen Receive Health Canada Approval for MS Use of
Tysabri™ II-76
Exelon Patch Wins EU Approval for Alzheimer's Treatment II-77
Isis Pharma Receives Orphan Drug Designation for ISIS333611 II-77
9. RECENT INDUSTRY ACTIVITY II-78
Lundbeck Acquires LifeHealth II-78
StemCells Acquires Stem Cell Sciences II-78
Oryzon Takes Over Crystax Pharmaceuticals II-78
JANSSEN Acquires Elan's Alzheimer's Immunotherapy Program II-79
Hisamitsu Takes Over Noven Pharmaceuticals II-79
Lundbeck Takes Over Ovation Pharmaceuticals II-80
Valeant Pharmaceuticals Takes Over Dow Pharmaceutical Sciences II-80
Genzyme Acquires Assets of Targeted Genetics Corporation II-80
Merck Takes Over Insmed's Follow-on Biologics Assets II-80
NeuroSearch Reacquires Global Rights to ACR16 II-81
Biovail Acquires Worldwide Rights to Tetrabenazine II-81
Raptor Pharmaceuticals Merges with TorreyPines II-81
iZumi Bio Merges with Pierian; Forms iPierian, Inc. II-82
Cell Genesys Merges with BioSante Pharmaceuticals II-82
CeNeRx BioPharma Secures Marketing and Development Rights for
CXB909 II-82
Laureate Pharma and ZZ Biotech Ink Agreement II-82
QxPharma Limited Signs Agreement with Patheon II-83
Cambridge Labs Signs New Agreements to Market Xenazine® in
North America II-83
Shire and UCB Ink Agreement II-83
NeuroNova and Genentech Signs Agreement for VEGF Use in ALS
Treatment II-84
Biovail to Acquire North American Rights to Fipamezole from
Santhera II-84
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane II-84
KineMed Collaborates with Bristol-Myers Squibb II-85
Vitae Pharmaceuticals Collaborates with Boehringer Ingelheim II-85
Insmed Inks Deal with IDIS to Organize NPPs for IPLEX™ II-85
Genzyme Corp. and Bayer HealthCare Sign Agreement II-86
CHDI Foundation Inks Agreement with AMRI for Drug Discovery II-86
Addex Pharmaceuticals Inks Licensing Agreement with Merck II-86
Acccera Sets Up Neuera Pharmaceuticals II-87
Evotec Inks Research Agreement with Biogen Idec II-87
ALS TDI and Asklepios to Develop ALS Therapy Delivery
Alternatives II-87
Evotec Extends Collaboration with Boehringer Ingelheim II-88
Neuralstem Collaborates to Develop Neural Stem Cell Therapies II-88
Eisai and Pfizer Ink Agreement II-88
BioAdvance Invests in TREVENTIS Corp. II-88
AstraZeneca Announces Milestone Payments to Targacept for
AZD3480 Program II-89
Suven Life Sciences Secures Two Patents in the US II-89
Eisai Terminates Contract with Nitto Denko Corporation II-89
MJFF Awards Grants to Targacept II-89
Metabolic Solutions Receives Grant from Alzheimer's Drug
Discovery Foundation II-90
Medical Research Council and Wellcome Trust to Fund
Neurodegeneration Research II-90
Biovail Acquires Prestwick Pharmaceuticals II-90
GlaxoSmithKline Acquires Sirtris Pharmaceuticals II-91
Newron Pharmaceuticals Acquires Hunter-Fleming II-91
SYGNIS Pharma Purchases Amnestix II-91
Proximagen Neuroscience Acquires Cambridge Biotechnology II-91
Teva Acquires Barr Pharmaceuticals II-92
Eisai Acquires MGI Pharma II-92
Ovation Pharmaceuticals Acquires License to Commercialize
Xenazine® in the US II-92
Targeted Genetics Acquires Rights to the siRNA Development
Program II-92
Insmed Obtains Royalty-Free Global Rights for IPLEX™ II-93
Pfizer and Serenex Ink Agreement II-93
Dr. Reddy's Laboratories Inks Agreement with Sygnis Pharma II-94
Cambridge Labs Inks and Renews Agreements in Multiple Nations II-94
CHDI Inked Collaboration Agreements with Galapagos II-94
Power3 Medical Products and StemTroniX Sign Letter of Intent II-94
ALS Therapy Development Institute and Allen Institute Ink
Agreement II-95
Yissum Inks Licensing Agreement with Eucalyptus II-95
GlaxoSmithKline Biologicals Enters into Licensing Agreement
with AFFiRiS II-95
Neurologix and Aegera Therapeutics Ink Licensing Agreement II-96
Neurobiological Inks Licensing Agreement with BIAR II-96
Raptor Pharma Forms Collaboration with CHU d'Angers for Phase
II Trial II-96
Amorfix Completes Research Partnership with Biogen Idec II-97
Apitope Raises Financing for Developing Multiple Sclerosis
Compound II-97
Pipex Pharmaceuticals Changes Corporate Name to Adeona
Pharmaceuticals II-97
MethylGene Terminates Collaboration Agreement with EnVivo
Pharmaceuticals II-98
Varinel Receives Fund from Alzheimer's Drug Discovery Foundation II-98
PharmatrophiX Receives Grants from Alzheimer's Drug Discovery
Foundation II-98
Eisai Acquires Morphotek II-98
Transition Therapeutics Acquires NeuroMedix II-99
Merz Licenses Anti-Alzheimer's Drug Technology from TAU II-99
Intellect Neurosciences Inks Agreement with CHDI Foundation to
Evaluate Potential of OXIGONTM II-99
Intellect Signs Licensing Agreement with Immuno- Biological
Laboratories II-99
Boehringer Ingelheim Signs R&D Agreement with Ablynx II-100
Evotec Teams Up with Boehringer Ingelheim II-100
Siemens Medical Signs Partnership Agreement with Wyeth II-100
Pipex Pharma Signs Agreement for Evaluation of COPREXA II-100
Digilab Receives Notice of Allowance for New Alzheimer's
Biomarker II-100
Pfizer Joins Forces with Genizon for AD II-101
Avicena Teams Up with NINDS for Phase III Trial of PD-02 II-101
QSV and Artielle Sign Contract to Produce RTL-1000 (To be
added to Canada) II-101
ALS TDI Selects Microbix to Manufacture Adenoviruses II-101
Maas BiolAB Receives SBIR Grant for ALS Study II-102
10. FOCUS ON SELECT GLOBAL PLAYERS II-103
Amarin Corporation PLC (Ireland) II-103
AstraZeneca PLC (UK) II-103
Avanir Pharmaceuticals, Inc. (US) II-103
Avigen, Inc. (US) II-104
Bayer Schering Pharma AG (Germany) II-104
Boehringer Ingelheim GmbH (Germany) II-104
Biogen Idec Inc. (US) II-105
Bristol-Myers Squibb Co. (USA) II-106
Biovail Corporation (Canada) II-106
Ceregene, Inc. (US) II-107
Eisai, Inc. (USA) II-107
Elan Pharmaceuticals (US) II-107
Eli Lilly and Company (USA) II-107
Forest Laboratories, Inc. (US) II-108
GlaxoSmithKline PLC (UK) II-109
H. Lundbeck A/S (Denmark) II-109
Merz Pharmaceuticals GMBH (Germany) II-110
Merck Serono SA (Switzerland) II-110
Mitsubishi Tanabe Pharma Corporation (Japan) II-111
Neurologix, Inc. (US) II-111
NeuroSearch A/S (Denmark) II-111
Novartis AG (Switzerland) II-112
Pfizer, Inc. (US) II-113
Sanofi-aventis S.A (France) II-113
Shire Pharmaceuticals Group PLC (UK) II-114
Teva Pharmaceutical Industries Limited (Israel) II-114
Valeant Pharmaceuticals International (US) II-115
Wyeth Pharmaceuticals, Inc. (US) II-115
11. GLOBAL MARKET PERSPECTIVE II-117
Analytics by Geographic Region II-117
Table 9: World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-117
Table 10: World 10-Year Perspective for Neurodegenerative
Drugs by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Europe and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-118
Analytics by Disease Type II-119
Table 11: World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Disease Type - Alzheimer's
Disease, Parkinson's Disease, Multiple Sclerosis,
Amyotrophic Lateral Sclerosis and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-119
Table 12: World 10-Year Perspective for Neurodegenerative
Drugs by Disease Type - Percentage Breakdown of Dollar Sales
for Alzheimer's Disease, Parkinson's Disease, Multiple
Sclerosis, Amyotrophic Lateral Sclerosis and Others for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-120
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current & Future Analysis III-1
AD Market Overview III-1
Approval of Cholinesterase Inhibitors for MCI to Drive Market III-1
Status of AD Drugs III-2
Prevalence III-2
Table 13: US Prevalence of Alzheimer's Disease for
2005-2010 (includes corresponding Graph/Chart) III-3
PD Market Overview III-3
Levodopa/Carbidopa on Declining Spree III-3
Patent Expiry Status III-3
Patent Expiry Status of Parkinson's Disease Drugs in the US III-3
Prevalence III-4
Increased Incidence and Rise in Drug Prices to Drive Growth
in MS Market III-4
Clinical Trials III-4
Product Launches III-5
Strategic Corporate Developments III-7
Key Players III-18
B.Market Analytics III-22
Table 14: US Recent Past, Current and Future Analysis for
Neurodegenerative Drugs Market - Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-22
2. EUROPE III-23
A.Market Analysis III-23
Current & Future Analysis III-23
Alzheimer's and Parkinson's Prevalence in Europe III-23
Table 15: European Alzheimer's Disease Prevalence by
Country/Region: Number of Patients for Germany, France, UK,
Italy, Spain, and Rest of Europe in Thousands For Years
2001 through 2010 (includes corresponding Graph/Chart) III-23
Table 16: European Parkinson's Disease Prevalence by
Country/Region: Number of Patients for Germany, France, UK,
Italy, Spain, and Rest of Europe in Thousands for Years
2001 through 2010 (includes corresponding Graph/Chart) III-24
Table 17: Multiple Sclerosis Prevalence in Select European
Countries for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-25
Low Penetration to Fuel Growth in European MS DMDs Market III-25
Clinical Trials III-25
Product Launches/Approvals III-27
Strategic Corporate Developments III-28
Key Players III-31
B.Market Analytics III-36
Table 18: European Recent Past, Current and Future Analysis
for Neurodegenerative Drugs by Country/ Region - France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2015 (includes corresponding Graph/Chart) III-36
Table 19: European 10-Year Perspective for Neurodegenerative
Drugs by Country/Region - Percentage Breakdown of Dollar
Sales for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2006, 2009 and 2015 (includes
corresponding Graph/Chart) III-37
3. REST OF WORLD III-38
A.Market Analysis III-38
Current & Future Analysis III-38
Canada - High Prevalence Rates for Multiple Sclerosis III-38
Table 20: Multiple Sclerosis Prevalence in Canada For Years
2001 through 2010 (includes corresponding Graph/Chart) III-38
Incidence of Multiple Sclerosis on the Rise in India III-39
Table 21: Multiple Sclerosis Prevalence in India For Years
2001 through 2010 (includes corresponding Graph/Chart) III-39
Alzheimer's and Parkinson's Prevalence in Canada III-40
Table 22: Alzheimer's and Parkinson's Diseases and Multiple
Sclerosis Prevalence in Canada For Years 2001 through 2010
(includes corresponding Graph/Chart) III-40
Alzheimer's and Parkinson's Prevalence in Japan III-40
Table 23: Alzheimer's and Parkinson's Diseases Prevalence
in Japan for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-40
Alzheimer's Prevalence in Asia-Pacific III-41
Table 24: Alzheimer's Disease Prevalence in Asia-Pacific by
Country: Number of Patients for Australia, India,
Philippines and Rest of Asia-Pacific in Thousands For Years
2001 through 2010 (includes corresponding Graph/Chart) III-41
Clinical Trials III-41
Research Studies/Other Developments III-42
Product Launches/Approvals III-42
Strategic Corporate Developments III-43
Select Players III-44
B.Market Analytics III-46
Table 25: Rest of World Recent Past, Current and Future
Analysis for Neurodegenerative Drugs Market - Annual Sales
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-46
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 165 (including Divisions/Subsidiaries - 190)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 93
Canada 6
Japan 8
Europe 61
France 6
Germany 12
The United Kingdom 12
Italy 3
Spain 3
Rest of Europe 25
Asia-Pacific (Excluding Japan) 18
Middle-East 4
------------------------------------------
To order this report:
Drug and Medication Industry: Global Neurodegenerative Drugs industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Global Neurodegenerative Drugs industry
http://www.reportlinker.com/p0197211/Global-Neurodegenerative-Drugs-industry.html
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 165 companies including many key and niche players such as Amarin Corporation PLC, AstraZeneca PLC, Avanir Pharmaceuticals, Inc., Avigen, Inc., Bayer Schering Pharma AG, Boehringer Ingelheim GmbH, Biogen Idec Inc., Bristol-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc., Elan Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Merck Serono SA, Mitsubishi Tanabe Pharma Corporation, Neurologix, Inc., NeuroSearch A/S, Novartis AG, Pfizer, Inc., Sanofi-aventis S.A, Shire Pharmaceuticals Group PLC, Teva Pharmaceutical Industries Limited, Valeant Pharmaceuticals International, and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Advertisement
NEURODEGENERATIVE DRUGS MCP-6313
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Alzheimer's Disease I-3
Parkinson's Disease I-4
Multiple Sclerosis I-4
Amyotrophic Lateral Sclerosis I-4
Others I-4
Huntington's Disease I-4
Neuropathic Pain I-4
Prion Disease I-5
II. EXECUTIVE SUMMARY
1. GLOBAL MARKET OVERVIEW II-1
Global Market Analysis II-1
Global Market Analysis by Disease Type II-1
Neurodegenerative Drugs - The Next Big Thing in Healthcare II-2
Alzheimer's and Parkinson's Market II-2
Factors Affecting the Market II-3
Major Growth Drivers Ahead II-3
Major Growth Inhibitors II-3
Rapid Growth of Aging Population II-3
Table 1: Global 65+ Age Group Population in Millions
(includes corresponding Graph/Chart) II-4
Higher Alzheimer's and Parkinson's Prevalence II-4
Price Hikes and Government Caps II-4
Future Holds Promise! II-4
Research & Development II-5
Neuroscience Research Focused on Neurodegenerative Diseases II-5
Neuroscience Research Advances to Make a Mark II-6
Summary of Major Neuroscience Research Developments in 2009 II-6
2. A REVIEW OF SELECT NEURODEGENERATIVE DRUGS MARKETS II-7
A. Alzheimer's Market in Review II-7
The AD Epidemiology II-7
Table 2: World Alzheimer's Disease Prevalence by
Country/Region: Number of Patients in US, Canada, Japan,
Europe (Germany, France, UK, Italy, Spain and Rest of
Europe), Asia-Pacific (Australia, India, Philippines and
Rest of Asia-Pacific), Brazil and Rest of World in
Thousands for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-7
Table 3: Alzheimer's Disease Statistics in Top Seven
Countries (US, Japan, Germany, France, UK, Italy and
Spain): Number of Patients Diagnosed and Treated by Disease
Severity (Mild Stage, Moderate Stage, and Late Stage) in
Thousands for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-8
The Impact of Dementia II-8
A Look At AD Demographics II-8
A Global Overview II-9
Geographic Overview II-10
Growth Drivers II-10
Aging Baby Boomers - The Market's Growth Engine II-10
Table 4: AD Frequency Rates in the US and Europe:
Percentage Share by Age Group (includes corresponding
Graph/Chart) II-10
Unmet Medical Needs Drive Market Growth II-11
Growth Restrains II-11
Misdiagnosis II-11
Lack of Awareness II-11
High Cost of Treatment II-11
Market Outlook for Anti-AD Drugs II-11
Cholinesterase Inhibitors - The Leader, but Not Strong
Growth Contender II-12
NMDA Receptor Antagonists - Dynamic Growth Potential,
Albeit A Small Base II-12
Approval of Anti-AD Drugs (Cholinesterase Inhibitors) in
Select Countries II-13
Competitive Landscape II-13
B. The Parkinson's Market in Review II-14
The PD Epidemiology II-14
Table 5: World Parkinson's Disease Prevalence by
Country/Region: Number of Patients in the US, Canada,
Japan, Europe (Germany, France, UK, Italy, Spain and Rest
of Europe), China and Rest of World in Thousands for Years
2001 through 2010 (includes corresponding Graph/Chart) II-14
A Global Overview II-15
Dominance of Dopamine Agonists II-15
Stalevo Continues to Outshine II-15
The Slippery Path to Clinical Success II-15
Market Drivers II-16
Emergence of Dopamine Agonists as First Line Treatment II-16
The Debut of Stalevo II-16
High Unmet Clinical Needs II-16
Market Inhibitors II-16
Lack of Awareness and Under-diagnosis II-16
Limitations of Existing Medicines II-17
Restricted Period Use of Dopamine Agonists II-17
Generic Competition from L-Dopa and Carbidopa II-17
C. The Multiple Sclerosis Market in Review II-17
The MS Epidemiology II-17
Table 6: World Multiple Sclerosis Prevalence in Thousands
by Select Countries for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-18
Facts About Multiple Sclerosis II-18
Market Overview II-19
Interferon-based Drugs Lead Multiple Sclerosis Drugs Market II-19
High Unmet Need and Rich Pipeline to Expand MS Market II-19
Sales Dip Inevitable for Current Therapies II-20
Tough Times Ahead for Betaseron II-21
Competitive Landscape II-21
Table 7: Global Multiple Sclerosis Market by Leading Drugs
(2008 & 2009): Percentage Share Breakdown for Copaxone,
Avonex, Rebif, Betaseron, and Tysabri (includes
corresponding Graph/Chart) II-21
D. The ALS Market in Review II-22
The ALS Epidemiology II-22
Market Overview II-23
Sanofi-aventis - The ALS Drugs Market Leader II-23
E. The Huntington's Market in Review II-23
The HD Epidemiology II-23
Market Outlook II-24
F. Neuropathic Pain Market in Review II-25
Market Overview II-25
G. Prion Disease II-25
Disease Origin II-25
3. FUTURE THERAPIES II-26
Alzheimer's Disease II-26
Select Pipeline Drugs for Alzheimer's Disease II-26
Parkinson's Disease II-26
Select Pipeline Drugs for Parkinson's Disease II-27
Huntington's Disease II-27
Select Pipeline Drugs for Treatment of Huntington's Disease II-27
Multiple Sclerosis II-28
Oral Pipeline Drugs to Alter Market Dynamics in MS Therapies II-28
Select Pipeline Drugs for Multiple Sclerosis II-29
Amyotrophic Lateral Sclerosis II-29
Select Pipeline Drugs for Amyotrophic Lateral Sclerosis II-29
4. NEURODEGENERATIVE DISEASES OVERVIEW II-30
Neurodegeneration II-30
An Overview of Factors that Link Neurodegenerative Diseases II-30
Genetics II-30
Intracellular Mechanisms II-30
Protein Degradation Pathways II-30
Mitochondrial Dysfunction II-31
Axonal Transport II-31
Programmed Cell Death II-31
An Overview of Select Major Neurodegenerative Diseases II-32
Alzheimer's Disease II-32
Definition II-32
Cause II-33
Diagnoses II-33
Prevention II-33
Treatment II-33
Anti-AD Drug Classes and Approved Products II-34
Parkinson's Disease II-34
Definition II-34
Cause II-34
Diagnosis II-35
Therapeutic Treatment II-35
List of Drugs Available for the Treatment of Parkinson's
Disease II-35
Surgical Intervention II-36
Multiple Sclerosis II-36
Definition II-36
Types of Multiple Sclerosis II-36
Table 8: Prevalence of Different Types of Multiple
Sclerosis (includes corresponding Graph/Chart) II-37
Etiology II-37
Pathology II-37
Treatment II-38
List of Approved Multiple Sclerosis Drugs II-38
Huntington's Disease II-38
Definition II-38
Prognosis II-39
The Three Stages of HD II-39
Symptoms and Signs II-40
List of Physical, Psychiatric and Cognitive Symptoms in
Huntington's Disease II-40
Diagnosis II-40
Treatment II-41
Amyotrophic Lateral Sclerosis (ALS) II-41
Definition II-41
Types of ALS II-42
Familial ALS II-42
Sporadic ALS II-42
Guamanian ALS II-42
Etiology II-42
Symptoms II-43
Diagnosis II-44
Treatment II-44
5. AN OVERVIEW OF NEURODEGENERATIVE DRUGS FOR SELECT DISEASES II-46
Neurodegenerative Drugs for Alzheimer's Disease II-46
NMDA Receptor Antagonists (NMDARA) II-46
Memantine II-46
Cholinesterase Inhibitors (ChEIs) II-47
Donepezil (Aricept) II-47
Rivastigmine (Exelon) II-47
Galantamine Hydrobromide (Razadyne) II-47
Tacrine (Cognex) II-48
Other Alternatives II-48
Vitamin E II-48
Estrogen Therapy II-48
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) II-48
Gingko Biloba II-49
Neurodegenerative Drugs for Parkinson's Disease II-49
Dopaminergic Agents II-49
Levodopa/Carbidopa II-49
Dopamine Agonists II-50
Bromocriptine/Parlodel II-50
Ropinirole/Requip II-50
Pramipexole/Mirapex II-50
Cabergoline/Dostinex II-50
Apomorphine/Apokyn II-50
Other PD Drugs II-51
COMT Inhibitors II-51
MAO-B Inhibitors II-51
Dopamine Amplifiers II-51
Anticholinergics II-52
Neurodegenerative Drugs for Huntington's Disease II-52
Tetrabenazine II-52
Others II-53
Neurodegenerative Drugs for Multiple Sclerosis II-53
Interferon Drugs II-53
Beta Interferon Drugs for the Treatment of Multiple Sclerosis II-54
Non-Interferon Drugs II-54
Non-Interferon Drugs for the Treatment of Multiple Sclerosis II-54
Neurodegenerative Drugs for Amyotrophic Lateral Sclerosis II-54
Rilutek II-55
Symptomatic Treatment II-55
6. NEURODEGENERATIVE RESEARCH II-57
Neurologix's Non-dopamine Gene Therapy for PD II-57
Cell Cure's Cell Replacement Therapy for PD II-57
Researches Developing Neuroprotective Agent for PD II-57
UT Southwestern Researchers Study New Compound for HD II-58
UCLA Scientists Identify Molecular Switch Capable of Blocking HD II-58
Repligen Reports Detection of HDAC 3 Drug Target for
Friedreich's Ataxia (US) II-58
Tel Aviv University Reports Stem Cell Cure for
Neurodegeneration (Israel) II-59
Cambridge Researchers Develop Novel Drug Targets for HD II-59
Emory Research Team Develops First Transgenic Monkey Model of HD II-59
KeyNeurotek Pharma Discloses Molecular Pathomechanism of HD
Mutation II-60
Researchers Identify New Gene for ALS II-60
Q Therapeutics and Johns Hopkins Research Team to Study GRPs
in ALS Model II-60
ALS TDI and CSC Collaborate to Study Stem Cells Use in ALS
Treatment II-61
Allen Institute and ALS TDI to Conduct ALS Study II-61
Life Technologies to Develop Neurodegenerative Disease Models II-61
Neuralstem and University of Michigan Collaborate for ALS
Research II-62
ALS TDI and MDA Collaborate for ALS Drug Discovery II-62
7. SELECT CLINICAL TRIALS II-63
Novartis Obtains Priority Review Status for Oral Fingolimod
from US FDA II-63
Medivation's Dimebon Fails to Meet End Points in Phase III Trial II-63
QR Pharma Annuls Phenserine Production II-63
Neurologix Begins Phase II Studies for Parkinson's Disease
Treatment (US) II-64
Biovail and ACADIA Complete Phase II Clinical Trials for
Pimavanserin (Canada, US) II-64
Merck Serono Announces Encouraging Phase III Results of Oral
Mylinax II-64
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT II-64
NeuroSearch Presents ACR16 as Novel Huntington's Disease Therapy II-65
Eli Lilly Launches Two Phase-III Trials for Solanezumab(i)
Worldwide (US) II-66
Teva and Active Biotech Obtains Fast Track Status from FDA for
Oral Laquinimod II-66
CytRx Initiates Phase II/III Clinical Trial for Arimoclomol II-67
Synosia Therapeutics Starts Stage-I Clinical Trial for SYN-120
(Switzerland) II-67
H. Lundbeck Begins Phase-I Clinical Tests for Lu 02-750 (Denmark) II-67
Anavex Life Sciences Selects FORENAP Pharma EURL for ANAVEX 2
-73 Phase-I Clinical Tests (Switzerland) II-67
Bayer Schering Pharma Completes Stage-II Trials for BAY 94-
9172 (Germany) II-68
Newron and Merck Serono Start Second Round of Phase III Tests
for Safinamide (Italy) II-68
Biogen Idec Secures Fast Track Designation from US-FDA for
PEGylated Interferon Beta-1a II-68
ExonHit Therapeutics Completes Phase-II Clinical Study for EHT
0202 (France) II-68
Kyowa Hakko Kirin to Start Phase-III Clinical Trials for
Istradefylline in Japan II-69
Medtronic and Alnylam Pharma Report Pre-Clinical Results of
ALN-HTT (US) II-69
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's
Treatment II-69
NeuroSearch Begins Critical Phase III Program with ACR16 II-70
Avicena to Proceeds with Phase III Trial of HD-02 II-70
Knopp Neurosciences Commences Phase II Study of KNS- 760704 II-70
Maas Biolab SBIR Initiates Phase II for Cyclosporin II-71
MediciNova Announces Phase II Clinical Trial Results of MN-166 II-71
Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02 II-71
EnVivo Pharmaceuticals Progresses on Major HDACi Program II-72
NeuroSearch Files CTA in Europe to Begin Clinical Phase III
Program with ACR16 II-72
8. PRODUCT INTRODUCTIONS/ APPROVALS/ DEVELOPMENTS II-73
Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to
treat Multiple Sclerosis II-73
Novartis Obtains Priority Review Status for Oral Fingolimod
from US FDA II-73
Accera Introduces Axona™ II-73
Eisai Receives Approval for Aricept® II-73
Copaxone Receives FDA Approval for Patients with First
Clinical Episode Suggestive of MS II-74
Copaxone Receives FDA Approval for Patients with First
Clinical Episode Suggestive of MS II-74
Novartis Obtains FDA Approval for Extavia II-74
ArmaGen Develops IgG-Decoy Receptor Fusion Protein (US) II-75
Knopp's KNS-760704 Receives EC Orphan Designation II-75
NeuroSearch Receives EMEA Approval for Huntexil™ Brand Name (
Europe) II-75
Cambridge Labs Receives Spanish Marketing Approval for
Tetrabenazine II-75
ArmaGen Technologies Secures Orphan Drug Designation for AGT-
181 from FDA (US) II-76
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation
for Cysteamine II-76
Elan and Biogen Receive Health Canada Approval for MS Use of
Tysabri™ II-76
Exelon Patch Wins EU Approval for Alzheimer's Treatment II-77
Isis Pharma Receives Orphan Drug Designation for ISIS333611 II-77
9. RECENT INDUSTRY ACTIVITY II-78
Lundbeck Acquires LifeHealth II-78
StemCells Acquires Stem Cell Sciences II-78
Oryzon Takes Over Crystax Pharmaceuticals II-78
JANSSEN Acquires Elan's Alzheimer's Immunotherapy Program II-79
Hisamitsu Takes Over Noven Pharmaceuticals II-79
Lundbeck Takes Over Ovation Pharmaceuticals II-80
Valeant Pharmaceuticals Takes Over Dow Pharmaceutical Sciences II-80
Genzyme Acquires Assets of Targeted Genetics Corporation II-80
Merck Takes Over Insmed's Follow-on Biologics Assets II-80
NeuroSearch Reacquires Global Rights to ACR16 II-81
Biovail Acquires Worldwide Rights to Tetrabenazine II-81
Raptor Pharmaceuticals Merges with TorreyPines II-81
iZumi Bio Merges with Pierian; Forms iPierian, Inc. II-82
Cell Genesys Merges with BioSante Pharmaceuticals II-82
CeNeRx BioPharma Secures Marketing and Development Rights for
CXB909 II-82
Laureate Pharma and ZZ Biotech Ink Agreement II-82
QxPharma Limited Signs Agreement with Patheon II-83
Cambridge Labs Signs New Agreements to Market Xenazine® in
North America II-83
Shire and UCB Ink Agreement II-83
NeuroNova and Genentech Signs Agreement for VEGF Use in ALS
Treatment II-84
Biovail to Acquire North American Rights to Fipamezole from
Santhera II-84
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane II-84
KineMed Collaborates with Bristol-Myers Squibb II-85
Vitae Pharmaceuticals Collaborates with Boehringer Ingelheim II-85
Insmed Inks Deal with IDIS to Organize NPPs for IPLEX™ II-85
Genzyme Corp. and Bayer HealthCare Sign Agreement II-86
CHDI Foundation Inks Agreement with AMRI for Drug Discovery II-86
Addex Pharmaceuticals Inks Licensing Agreement with Merck II-86
Acccera Sets Up Neuera Pharmaceuticals II-87
Evotec Inks Research Agreement with Biogen Idec II-87
ALS TDI and Asklepios to Develop ALS Therapy Delivery
Alternatives II-87
Evotec Extends Collaboration with Boehringer Ingelheim II-88
Neuralstem Collaborates to Develop Neural Stem Cell Therapies II-88
Eisai and Pfizer Ink Agreement II-88
BioAdvance Invests in TREVENTIS Corp. II-88
AstraZeneca Announces Milestone Payments to Targacept for
AZD3480 Program II-89
Suven Life Sciences Secures Two Patents in the US II-89
Eisai Terminates Contract with Nitto Denko Corporation II-89
MJFF Awards Grants to Targacept II-89
Metabolic Solutions Receives Grant from Alzheimer's Drug
Discovery Foundation II-90
Medical Research Council and Wellcome Trust to Fund
Neurodegeneration Research II-90
Biovail Acquires Prestwick Pharmaceuticals II-90
GlaxoSmithKline Acquires Sirtris Pharmaceuticals II-91
Newron Pharmaceuticals Acquires Hunter-Fleming II-91
SYGNIS Pharma Purchases Amnestix II-91
Proximagen Neuroscience Acquires Cambridge Biotechnology II-91
Teva Acquires Barr Pharmaceuticals II-92
Eisai Acquires MGI Pharma II-92
Ovation Pharmaceuticals Acquires License to Commercialize
Xenazine® in the US II-92
Targeted Genetics Acquires Rights to the siRNA Development
Program II-92
Insmed Obtains Royalty-Free Global Rights for IPLEX™ II-93
Pfizer and Serenex Ink Agreement II-93
Dr. Reddy's Laboratories Inks Agreement with Sygnis Pharma II-94
Cambridge Labs Inks and Renews Agreements in Multiple Nations II-94
CHDI Inked Collaboration Agreements with Galapagos II-94
Power3 Medical Products and StemTroniX Sign Letter of Intent II-94
ALS Therapy Development Institute and Allen Institute Ink
Agreement II-95
Yissum Inks Licensing Agreement with Eucalyptus II-95
GlaxoSmithKline Biologicals Enters into Licensing Agreement
with AFFiRiS II-95
Neurologix and Aegera Therapeutics Ink Licensing Agreement II-96
Neurobiological Inks Licensing Agreement with BIAR II-96
Raptor Pharma Forms Collaboration with CHU d'Angers for Phase
II Trial II-96
Amorfix Completes Research Partnership with Biogen Idec II-97
Apitope Raises Financing for Developing Multiple Sclerosis
Compound II-97
Pipex Pharmaceuticals Changes Corporate Name to Adeona
Pharmaceuticals II-97
MethylGene Terminates Collaboration Agreement with EnVivo
Pharmaceuticals II-98
Varinel Receives Fund from Alzheimer's Drug Discovery Foundation II-98
PharmatrophiX Receives Grants from Alzheimer's Drug Discovery
Foundation II-98
Eisai Acquires Morphotek II-98
Transition Therapeutics Acquires NeuroMedix II-99
Merz Licenses Anti-Alzheimer's Drug Technology from TAU II-99
Intellect Neurosciences Inks Agreement with CHDI Foundation to
Evaluate Potential of OXIGONTM II-99
Intellect Signs Licensing Agreement with Immuno- Biological
Laboratories II-99
Boehringer Ingelheim Signs R&D Agreement with Ablynx II-100
Evotec Teams Up with Boehringer Ingelheim II-100
Siemens Medical Signs Partnership Agreement with Wyeth II-100
Pipex Pharma Signs Agreement for Evaluation of COPREXA II-100
Digilab Receives Notice of Allowance for New Alzheimer's
Biomarker II-100
Pfizer Joins Forces with Genizon for AD II-101
Avicena Teams Up with NINDS for Phase III Trial of PD-02 II-101
QSV and Artielle Sign Contract to Produce RTL-1000 (To be
added to Canada) II-101
ALS TDI Selects Microbix to Manufacture Adenoviruses II-101
Maas BiolAB Receives SBIR Grant for ALS Study II-102
10. FOCUS ON SELECT GLOBAL PLAYERS II-103
Amarin Corporation PLC (Ireland) II-103
AstraZeneca PLC (UK) II-103
Avanir Pharmaceuticals, Inc. (US) II-103
Avigen, Inc. (US) II-104
Bayer Schering Pharma AG (Germany) II-104
Boehringer Ingelheim GmbH (Germany) II-104
Biogen Idec Inc. (US) II-105
Bristol-Myers Squibb Co. (USA) II-106
Biovail Corporation (Canada) II-106
Ceregene, Inc. (US) II-107
Eisai, Inc. (USA) II-107
Elan Pharmaceuticals (US) II-107
Eli Lilly and Company (USA) II-107
Forest Laboratories, Inc. (US) II-108
GlaxoSmithKline PLC (UK) II-109
H. Lundbeck A/S (Denmark) II-109
Merz Pharmaceuticals GMBH (Germany) II-110
Merck Serono SA (Switzerland) II-110
Mitsubishi Tanabe Pharma Corporation (Japan) II-111
Neurologix, Inc. (US) II-111
NeuroSearch A/S (Denmark) II-111
Novartis AG (Switzerland) II-112
Pfizer, Inc. (US) II-113
Sanofi-aventis S.A (France) II-113
Shire Pharmaceuticals Group PLC (UK) II-114
Teva Pharmaceutical Industries Limited (Israel) II-114
Valeant Pharmaceuticals International (US) II-115
Wyeth Pharmaceuticals, Inc. (US) II-115
11. GLOBAL MARKET PERSPECTIVE II-117
Analytics by Geographic Region II-117
Table 9: World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-117
Table 10: World 10-Year Perspective for Neurodegenerative
Drugs by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Europe and Rest of World Markets for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-118
Analytics by Disease Type II-119
Table 11: World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Disease Type - Alzheimer's
Disease, Parkinson's Disease, Multiple Sclerosis,
Amyotrophic Lateral Sclerosis and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-119
Table 12: World 10-Year Perspective for Neurodegenerative
Drugs by Disease Type - Percentage Breakdown of Dollar Sales
for Alzheimer's Disease, Parkinson's Disease, Multiple
Sclerosis, Amyotrophic Lateral Sclerosis and Others for Years
2006, 2009, and 2015 (includes corresponding Graph/Chart) II-120
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current & Future Analysis III-1
AD Market Overview III-1
Approval of Cholinesterase Inhibitors for MCI to Drive Market III-1
Status of AD Drugs III-2
Prevalence III-2
Table 13: US Prevalence of Alzheimer's Disease for
2005-2010 (includes corresponding Graph/Chart) III-3
PD Market Overview III-3
Levodopa/Carbidopa on Declining Spree III-3
Patent Expiry Status III-3
Patent Expiry Status of Parkinson's Disease Drugs in the US III-3
Prevalence III-4
Increased Incidence and Rise in Drug Prices to Drive Growth
in MS Market III-4
Clinical Trials III-4
Product Launches III-5
Strategic Corporate Developments III-7
Key Players III-18
B.Market Analytics III-22
Table 14: US Recent Past, Current and Future Analysis for
Neurodegenerative Drugs Market - Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-22
2. EUROPE III-23
A.Market Analysis III-23
Current & Future Analysis III-23
Alzheimer's and Parkinson's Prevalence in Europe III-23
Table 15: European Alzheimer's Disease Prevalence by
Country/Region: Number of Patients for Germany, France, UK,
Italy, Spain, and Rest of Europe in Thousands For Years
2001 through 2010 (includes corresponding Graph/Chart) III-23
Table 16: European Parkinson's Disease Prevalence by
Country/Region: Number of Patients for Germany, France, UK,
Italy, Spain, and Rest of Europe in Thousands for Years
2001 through 2010 (includes corresponding Graph/Chart) III-24
Table 17: Multiple Sclerosis Prevalence in Select European
Countries for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-25
Low Penetration to Fuel Growth in European MS DMDs Market III-25
Clinical Trials III-25
Product Launches/Approvals III-27
Strategic Corporate Developments III-28
Key Players III-31
B.Market Analytics III-36
Table 18: European Recent Past, Current and Future Analysis
for Neurodegenerative Drugs by Country/ Region - France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2015 (includes corresponding Graph/Chart) III-36
Table 19: European 10-Year Perspective for Neurodegenerative
Drugs by Country/Region - Percentage Breakdown of Dollar
Sales for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2006, 2009 and 2015 (includes
corresponding Graph/Chart) III-37
3. REST OF WORLD III-38
A.Market Analysis III-38
Current & Future Analysis III-38
Canada - High Prevalence Rates for Multiple Sclerosis III-38
Table 20: Multiple Sclerosis Prevalence in Canada For Years
2001 through 2010 (includes corresponding Graph/Chart) III-38
Incidence of Multiple Sclerosis on the Rise in India III-39
Table 21: Multiple Sclerosis Prevalence in India For Years
2001 through 2010 (includes corresponding Graph/Chart) III-39
Alzheimer's and Parkinson's Prevalence in Canada III-40
Table 22: Alzheimer's and Parkinson's Diseases and Multiple
Sclerosis Prevalence in Canada For Years 2001 through 2010
(includes corresponding Graph/Chart) III-40
Alzheimer's and Parkinson's Prevalence in Japan III-40
Table 23: Alzheimer's and Parkinson's Diseases Prevalence
in Japan for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-40
Alzheimer's Prevalence in Asia-Pacific III-41
Table 24: Alzheimer's Disease Prevalence in Asia-Pacific by
Country: Number of Patients for Australia, India,
Philippines and Rest of Asia-Pacific in Thousands For Years
2001 through 2010 (includes corresponding Graph/Chart) III-41
Clinical Trials III-41
Research Studies/Other Developments III-42
Product Launches/Approvals III-42
Strategic Corporate Developments III-43
Select Players III-44
B.Market Analytics III-46
Table 25: Rest of World Recent Past, Current and Future
Analysis for Neurodegenerative Drugs Market - Annual Sales
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-46
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 165 (including Divisions/Subsidiaries - 190)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 93
Canada 6
Japan 8
Europe 61
France 6
Germany 12
The United Kingdom 12
Italy 3
Spain 3
Rest of Europe 25
Asia-Pacific (Excluding Japan) 18
Middle-East 4
------------------------------------------
To order this report:
Drug and Medication Industry: Global Neurodegenerative Drugs industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
